Lycera Stock

lycera.comHealthcareFounded: 1900Funding to Date: $106.06MM

Lycera is a biopharmaceutical company that seeks to uncover new small molecule therapies for the treatment of autoimmune diseases and cancer.

Register for Details

For more details on financing and valuation for Lycera, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Lycera.

Register Today

Team

Management Team

Alex Howarth
Chief Financial Officer
William Sibold
Co-Chief Executive Officer & President
Bruce Goldsmith Ph.D
Chief Operating Officer and Chief Business Officer
Paul Sekhri
President, Co-Chief Executive Officer & Board Member
H. Jeffrey Wilkins MD
Chief Medical Officer

Board Members

Jeffrey Leiden Ph.D
Blackstone Life Sciences
Michael Hayden Ph.D
Pablo Cagnoni MD
Robert Kamen Ph.D
Mary Campbell
EDF Ventures
Nina Kjellson
InterWest Partners
Paul Sekhri
Steven Gillis Ph.D
ARCH Venture Partners
Kristina Burow
ARCH Venture Partners
Nicholas Simon
Blackstone Life Sciences
Finny Kuruvilla Ph.D
Blackstone Life Sciences
Timothy Mayleben

Other companies like Lycera in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM
Sector
Last Round Est. Valuation
$4.8B